Trial Profile
PDE5 Inhibition Via Tadalafil (Cialis) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary) ; Cancer vaccine MUC-1; Influenza virus RIV3 vaccine-(FluBlok); Poly ICLC
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2021 Status changed from active, no longer recruiting to completed.
- 04 Jun 2020 Planned End Date changed from 1 Jun 2020 to 19 Jun 2021.
- 29 Aug 2019 Planned End Date changed from 1 Apr 2021 to 1 Jun 2020.